eyeforpharma Philadelphia 2017: 6 in-depth conferences in one

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond, the 6 eyeforpharma Philadelphia 2017 sessions will focus on:

Commercial Leadership

  • Commercial Leadership: Healthcare Leadership: How Pharma Embraces a New Customer Engagement Paradigm
  • Executive Commitment: Recognize Patient Centricity as a Journey: and Spearhead Cultural Change
  • Business Transformation: Your Company Needs to be Disrupted: Corporate Activism for Value Creation
  • Technology Partnerships: Tech meets Pharma: Life Science Partnerships from Bench to Bedside
  • Healthcare Challenges: Approaching the Caregiver Cliff: How Pharma Should Support the Supporters
  • The Implementation Panel: From Words to Action, How to Become a Pharma Intrapreneur

Patients as Partners

  • Patient advocacy 2.0: Manage ‘local customer engagement' from pre to post launch
  • The future of pharma-stakeholder collaboration: Lessons learnt from partnering in the rare disease field
  • Where rubber hits the road: Can patient centricity grow the bottom-line?
  • Case studies on understanding and acting on patient concern

Customer Experience

  • Is the new sales strategy to de-prioritize targets?
  • Customer experience is the key to commercial excellence
  • It's the experience that counts!
  • Look after your customer's journey from start to finish
  • Sales rep 2.0: The new portrait of a customer facing role

Commercial Model Innovation

  • A holistic commercial view: integrate your sales and marketing teams
  • Leverage untapped opportunities with patient-centric selling
  • Customer centricity is key. Are you doing enough?
  • The Modern Marketer: how to stay ahead in a competitive landscape

Pharma's Triple Aim

  • Strengthen the patient ecosystem - improve treatment adherence beyond physician support
  • How to innovate and differentiate your patient assistance solutions
  • Understand factors driving patients' treatment choices
  • Free your engagement from uncertainty around compliance

Digital Transformation

  • Maximize capabilities of your commercial teams with technology
  • Stay ahead of the curve: How digital integration takes your customer’s experience further
  • The power of integrating digital across all aspects of your organization
  • Leveraging Digital: Navigating digital trends and technologies to maximize positive outcomes for patients

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

You can find full details of the meeting here.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Nearly 1 in 3 drugs found to have safety concerns …

How often are safety concerns raised about a drug after it's been approved by the FDA? Nicholas Downing, MD, of the Department of Medicine at Brigham and Women's Hospital...

Read more

Alzheimer's experts call for changes in FDA drug a…

Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, "Single Endpoint for New Drug Approvals for Alzheimer's Disease," ur...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]